(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and ...

Last year around this time, several leading drugmakers announced significant M&A deals to help fill their pipelines, including Bristol-Myers Squibb's ( BMY) proposed takeovers of Karuna and RayzeBio, ...

Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills.

The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.

Bristol Myers Squibb announced a collaboration agreement with three-year-old startup AI Proteins. According to its founder, ...

Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong ...

BioArctic AB (publ) has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s ...

We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look ...